Industry landscapes
The companies, capital and talent shaping healthtech in Hyderabad. Find the leaders. Understand the segments. See where the activity is.
An industry ecosystem,
measured in context.
24 featured companies from the funding, hiring, revenue and team-size leaderboards.
Locked revenue figures are available in Radar; the eight company financial previews stay the same throughout this page. A dash means the figure is outside these featured lists. Revenue years vary by company; the figures are not a like-for-like revenue comparison. Compare annual accounts ↗
A few useful ratios bring the size of this ecosystem into perspective.
33 of 478 tracked companies have open roles.
82 of 478 tracked companies have a recorded round.
Share of disclosed capital received by the three largest recorded recipients.
Midpoint of 157 rounds with a disclosed amount.
Scale is concentrated. Opportunity is broader. The three largest funding recipients hold 83.5% of disclosed capital, while 82.8% of tracked companies have no recorded funding round.
Explore the segments →Recorded company formation and disclosed funding across the complete annual series shown.
Sum of recorded funding rounds · USD
| Year | Funding (USD) | Founded | Raising |
|---|---|---|---|
| 2016 | $19.56M | 33 | 10 |
| 2017 | $29.33M | 34 | 20 |
| 2018 | $11.28M | 25 | 16 |
| 2019 | $13.24M | 37 | 21 |
| 2020 | $2.52M | 41 | 13 |
| 2021 | $29.18M | 44 | 11 |
| 2022 | $12.42M | 35 | 17 |
| 2023 | $11.21M | 32 | 12 |
| 2024 | $302.11M | 22 | 13 |
| 2025 | $7.76M | 16 | 7 |
Share of all disclosed company funding.
189 recorded rounds since 2016
Recorded participation in healthtech company rounds since 2016.
Backed by Global Innovation.
Backed by Fincity and Sankosh Agro Farms and others.
Backed by Tetra Soft and Brand Capital and others.
Backed by Kubera Cross-Border Fund.
Backed by Kubera Cross-Border Fund and IFC and others.
Backed by Chiranjeevi Konidala and Chamundeswara Nath Vankina and others.
Backed by AKAR Ventures and TriGeo Technologies and others.
Backed by IFC and Kubera Partners.
Backed by Timesgroup.
Backed by 360 One and Vikram Malhotra.
Backed by Soma Capital and Justin Mateen and others.
Annual accounts for reporting companies linked to this landscape, on like-for-like currency and reporting bases.
Display conversions use the dated reference rates above. Where a verified rate is unavailable, figures retain their source currency. Each reporting cohort keeps its currency and accounting basis separate.
FY2025 · annual statements grouped by reported fiscal year; exact entity periods remain on preview rows · 142 reporting entities from 200 eligible matches.
Sum of reporting-entity revenue; not Hyderabad market sales.
Combined result for the same cohort.
Combined net income ÷ combined revenue.
The middle covered reporting entity.
59 of 142 covered entities.
Share of covered revenue from the five largest entities.
Reported cohort totals by year; coverage is stated for every period.
Bar height shows revenue. Changes in coverage can affect totals.
FY2025 · 142 reporting entities
Up to eight fixed company previews show financial amounts. Search and sort the wider company list, then continue in Radar.
| Company / reporting entity | Revenue | Net profit / loss | Net margin | Revenue growth | Total assets |
|---|---|---|---|---|---|
| Primera Medical Technologies ↗U72200TG2015PTC099170 | ₹479.4 crore | ₹50.1 crore | +10.5% | — | ₹268.3 crore |
| Sensa Core ↗U74999TG2006PTC051992 | ₹319.1 crore | ₹57.0 crore | +17.9% | — | ₹522.4 crore |
| CallHealth ↗U85100TG2013PTC091009 | ₹64.4 crore | ₹-11.0 crore | -17.1% | — | ₹57.3 crore |
| Huwel Life ↗U33111TG2015PTC097596 | ₹15.4 crore | ₹-1.3 crore | -8.7% | — | ₹59.5 crore |
| Karma Primary Healthcare ↗U85100RJ2014PTC046047 | ₹8.9 crore | ₹0.0 crore | +0.4% | — | ₹9.5 crore |
| Hearzap ↗U85100TG2013PTC086504 | ₹3.2 crore | ₹1.0 crore | +29.5% | — | ₹61.4 crore |
| HealthSignz ↗U72200TG2014PTC096187 | ₹1.1 crore | ₹-1.5 crore | -139.2% | — | ₹45.5 crore |
| Ocimum Biosolutions ↗U72100TG2001PLC036378 | ₹0.0 crore | ₹-0.9 crore | — | — | ₹23.3 crore |
Explore full company accounts and filings.
Choose “View accounts” to inspect an available company preview.
Each pair uses the same year, currency and reporting basis. Cohort overlap is disclosed.
| Industry | Covered / eligible | Revenue total | Median revenue | Net profit / loss | Aggregate margin | Profitable share | Overlap |
|---|
Available-account cohorts are not estimates of whole industries. Overlapping entities can occur in more than one cohort; do not add cohort totals.
Filed annual accounts for exact designated national identifiers. Every aggregate and peer pair uses one fiscal year, source currency and reporting basis; periods, coverage and overlap are explicit; 2026 partials are excluded.
The same up to eight reporting entities remain open across years, filters and sorts. Other company figures are available in Radar.
Source currencies and accounting bases stay separate. Missing accounts are excluded rather than treated as zero. Exact reporting periods appear on company previews. Annual totals can change with coverage and do not measure growth of a fixed company cohort.
How the Hyderabad companies on this page show up online: the sites people visit, the apps they install, and how often those apps ship.
6 of the 478 companies on this page carry a measured traffic record (1.3%); these are the largest of those, by monthly visits. The median among them is 277,809 visits.
| Company | Monthly visits | Authority | Mobile |
|---|---|---|---|
| Apollo 24|7apollo247.com | 4,046,701 | 64 | 92.1% |
| MedPlusmedplusmart.com | 1,554,728 | 73 | 90.8% |
| DoctorCdoctorc.in | 282,141 | 40 | 95.9% |
| SkeDocskedoc.com | 273,477 | 50 | 94.7% |
| Eyvaeyva.io | 66,989 | 24 | 98.9% |
| Sehatsehat.com | 2,757 | 28 | 0% |
Visits and authority are third-party web estimates, not company-reported figures.
74 of these companies (15.5%) publish at least one Android app — 148 apps in all, carrying 48.3M installs between them.
| App | Installs | Rating | Store category |
|---|---|---|---|
| Apollo 247 - Health & MedicineApollo 24|7 | 36.9M | 4.4 | Medical |
| MedPlus Mart - Online PharmacyMedPlus | 7.6M | 4.3 | Medical |
| DoctorCDoctorC | 1.4M | — | Medical |
| Ask Apollo — Consult Doctors, Ask Apollo | 1.2M | 3.2 | Medical |
| Apollo247 DoctorApollo 24|7 | 283.7K | 2.8 | Medical |
| Hearzap - Hearing Test AppHearzap | 193.5K | — | Medical |
| OHS Outlet Operationsmedplus(optival health solutions) | 94.2K | — | Business |
| CallHealth – Online HealthcareCallHealth | 85.5K | 3 | Medical |
| Vigo LifeVigocare | 78.9K | — | Medical |
| Birla HIL DistributoreSeal | 78.7K | — | Business |
Installs are lifetime totals to date at the June 2026 store reading — a measure of reach, not of people using an app today.
The busiest app inside each of this page’s own segments, with the quarterly release trend behind it (2023Q4–2026Q1).
| Segment | Apps | Installs | Leading app | Release trend |
|---|---|---|---|---|
| Healthcare Booking Platforms | 52 | 47.9M | Apollo 247 - Health & Medicine 36.9M | |
| Healthcare It | 87 | 357.2K | Vigo Life 78.9K | |
| Iot Applications | 3 | 157.7K | Birla HIL Distributor 78.7K | |
| Uber For Medicine Delivery | 2 | 154.3K | OHS Outlet Operations 94.2K | |
| Disease Self Management | 8 | 40.9K | Eyva 16.5K | |
| Life Sciences Tech | 6 | 36K | Medgini Chemist 34.8K | |
| Wearable Technology | 2 | 23.5K | Curapod 15.3K | |
| Employee Health It | 4 | 21.9K | Flip Health - Pocket Doctor 21.6K |
A company can carry several segment tags, so these rows overlap and should not be added together. Trend lines are zero-based and share one quarter grid, so a flat line is a quiet segment, not a missing one.
New apps published, beside apps whose most recent update landed in that quarter — the second bar is how much of the shelf is still being maintained.
Darker bars are new releases, lighter bars apps updated. 82 of 148 apps carry a release date. The series ends at 2026Q1, the last quarter that closed before the June 2026 reading.
Explore the segments behind the headline numbers.
Rank segments by scale, hiring or disclosed funding.
Companies can sit in several segments. Counts and funding overlap.
The largest measured segment in this report snapshot.
18 companies hiring · $83.79M disclosed funding
Explore in RadarCommon revenue models; a company can use more than one.
Recorded corporate activity linked to companies in this landscape.
Avio Smart Market Stack has signed a shareholders’ agreement to acquire a minority stake in Hyderabad-based Huwel Lifesciences.
We are pleased to share that our client, Sensa Core Medical Instrumentation Private Limited (“SensaCore”), has successfully raised INR 650Cr from Motilal Oswal Alternates, marking one of the largest minority deals in the diagnostic consumables segment.
Bartronics India Limited (BIL), a publicly listed technology and services company, has announced a strategic investment of up to ₹50 crore in Huwel Life Sciences Pvt Ltd, a Hyderabad-based leader in molecular diagnostics.
Mapmygenome, a Hyderabad-headquartered AI-driven genomic and microbiome testing company has announced a strategic acquisition of Microbiome Insights, a global leader in microbial sequencing.
Biomira Inc. announced Monday that it has purchased all remaining outstanding shares of ADI Diagnostics Inc. from Cambridge Biotech Corp.
Primera raised $21M in a Series B round led by Abingworth and joined by Interwest Partners; existing investors Malaysian Technology Development Corp., MPM Capital, Burrill & Co. and the Invus Group also participated
Initial public offer of upto 35,00,000 equity shares of face value of Rs.10/- each (the equity shares) of Multiplier AI Limited (the company or the issuer) at an issue price of Rs.[*]/- per equity share (including share premium of Rs.[*]/- per equity share) for cash, aggregating up to Rs.[*] crores (public issue) out of which [*] equity shares of face value of Rs.10/- each, at an issue price of Rs.[*]/- per equity share for cash, aggregating Rs.[*] crores will be reserved for subscription by the market maker to the issue (the market maker reservation portion). The public issue less market maker reservation portion i.e. issue of [*] equity shares of face value of Rs.10/- each, at an issue price of Rs.[*]/- per equity share for cash, aggregating upto Rs.[*] crores is herein after referred to as the net issue. The public issue and net issue will constitute [*]% and [*]% respectively of the post-issue paid-up equity share capital of the company.The price band and the minimum bid lot will be decided by the company in consultation with the brlm.
Althion, a Hyderabad-based water-tech company, has successfully raised Rs 3.6 crore in a pre-Series A funding round.
Hearzap will expand its roots in the eastern regions following this acquisition.
Digital healthcare startup Karma Primary Healthcare has successfully raised ₹11 crore (approximately $1.3 million) in its Series A funding round, with significant investment from UBS Optimus Foundation.
Top 7 categories among 52 recorded events in the 24-month window.
2 companies with recorded IPO activity
IPO · BSE and NSE1 reports
IPO1 reports
2 recorded events
suspended drug licenseAssistant Director of Drugs Control Administration
suspension of drug license for 7 daysAssistant Director, Drugs Control Administration, Telangana
Reported company results in the recorded window.
Median across 12 reported growth observations; companies may contribute multiple periods.
Company-linked deal reports; status is preserved as recorded.
| Acquirer → target | Status | Date | Value / context |
|---|---|---|---|
| Avio Smart Market Stack Limited→huwel lifesciences | Announced | 2026-03-02 | Not stated in snapshot |
| motilal oswal alternates→Sensa Core ↗ | Announced | 2025-12-23 | $72.0M |
| KKR, TPG, Kedaara Capital, and Multiples Alternate Asset Management→Sensa Core ↗ | Rumored | 2025-07-29 | $300.0M |
| MapMyGenome→microbiome insights | Announced | 2025-05-29 | Not stated in snapshot |
| Biomira Inc.→ADI Diagnostics | Announced | 2025-02-14 | Not stated in snapshot |
| Hearzap→Speech and Hearing Care | Completed | 2024-09-05 | Not stated in snapshot |
A discussion or rumour is not a completed transaction. An unstated value is not zero.
711 postings in the preceding 12 months. The full 823-posting snapshot covers 472 employers.
0 tracked postings mention remote work.
459 postings specify a level.
Top skills across 823 tracked postings in the available jobs snapshot.
Median across 95 postings with pay data, expressed in USD.
| Company | Employees |
|---|---|
| medplus(optival health solutions) ↗ | 501 |
| CallHealth ↗ | 284 |
| Sangam Health Care Products ↗ | 284 |
| Sensa Core ↗ | 257 |
| Medvarsity ↗ | 201 |
| Hearzap ↗ | 94 |
| Vigocare ↗ | 87 |
| Drucare ↗ | 70 |
394 founders and chief executives across 273 companies.
Callhealth, ex-Tech Mahindra, ex-Mahindra Satyam, Loyola College, 1986
Ex- Mahindra Satyam. International School of Business and Media MBA
Ex – CTO Competence India, Infinite Computer Solutions, GE, IBM, Mansoft. B.Tech.
All India Institute of Speech and Hearing, Manasagangothri, Mysore MS 2006
Ex-Co-Founder Biofi, NYU Langone Medical Center, Ford Motor, United Nations Development. UVCE, Bangalore 1991
Ex-Co-Founder Shoutt, Sleepyhead, Oracle. Jawaharlal Nehru Technological University BTech 2007, Brown University MSc 2009
Apollo 24, ex-Healthhiway, ex-Ngpay Acquired By Flipkart, Stanford University, 1998
Ex-Johnson & Johnson, Global Cardiac Monitors. University of Mumbai BE 2002, University of Houston 2004…
Drucare, ex-Government, EC Council, 2016
TiE, ex-Multiplier IT Solutions India, Capgemini, iflex solutions. BITS Pilani BE 2003, SPJIMR SP Jain Institute of Management & Research MBA 2007
Microbiome Insights, nasscom, World Economic Forum, The Aspen Institute. Indian Institute of Technology, Kharagpur BSc 1995…
Ex-My Ally, VALUE CHUNKS, Deloz Technologies. Jawaharlal Nehru Technological University BTech 2016
70 profiles with education records.
15 profiles with prior-work records.
Profiles cover recorded founders and leaders; contact details remain in Radar.
32,580 articles in the measured 12-month window.
Healthtech coverage tagged Hyderabad · articles per complete quarter
| Quarter | Articles |
|---|---|
| 2021Q2 | 4,773 |
| 2021Q3 | 3,929 |
| 2021Q4 | 3,723 |
| 2022Q1 | 4,496 |
| 2022Q2 | 5,440 |
| 2022Q3 | 6,749 |
| 2022Q4 | 7,078 |
| 2023Q1 | 8,147 |
| 2023Q2 | 6,399 |
| 2023Q3 | 6,470 |
| 2023Q4 | 6,803 |
| 2024Q1 | 9,171 |
| 2024Q2 | 6,711 |
| 2024Q3 | 6,983 |
| 2024Q4 | 8,506 |
| 2025Q1 | 9,512 |
| 2025Q2 | 8,856 |
| 2025Q3 | 7,525 |
| 2025Q4 | 8,562 |
| 2026Q1 | 8,295 |
Article volume measures coverage, not market sales.
72 recorded company events across 12 companies; percentages use that event total.
Healthtech coverage tagged Hyderabad · ranked by full-period article count.
Recent and prior counts use the source comparison windows.
India comparison coverage
| Keyword | Recent | Prior | Change |
|---|---|---|---|
| tariff negotiations | 11,620 | 5,680 | 105% |
| bilateral trade | 4,610 | 2,437 | 89% |
| trade dispute mechanisms | 4,511 | 2,203 | 105% |
| trade barrier reduction | 4,496 | 2,440 | 84% |
| trade facilitation commitments | 4,327 | 2,201 | 97% |
| countries | 4,193 | 1,860 | 125% |
| free trade deals | 4,078 | 2,429 | 68% |
| multilateral diplomacy | 3,918 | 2,723 | 44% |
| diplomatic strategies | 3,816 | 2,350 | 62% |
| bilateral trade imbalance | 3,281 | 2,044 | 61% |
| odi cricket | 6,036 | 9,660 | -38% |
| limited overs cricket | 5,777 | 9,308 | -38% |
| odi tactics | 5,628 | 8,746 | -36% |
| odi series | 5,256 | 8,324 | -37% |
| odi tournaments | 5,032 | 8,067 | -38% |
India comparison coverage
territories, disputed islands, test cricket
44.3% critical · 27.2% positivepre-ipo valuation, ipo prospectus, ipo pricing
49.3% critical · 46.7% positivegdp growth rate, economic output growth, economic growth statistics
46.9% critical · 50.7% positiveHealthtech coverage tagged Hyderabad. Topic labels describe recorded classifications and can include broad context.
3,029 papers in the recorded india scope.
Tone counts: 2,771 positive · 35 neutral · 223 negative.
Landmark: Barriers and facilitators to utilizing digital health technologies by healthcare professionals
Landmark: Digital mental health apps and the therapeutic alliance: initial review
Landmark: Feature selection and classification systems for chronic disease prediction: A review
Common problems researchers identify · 0123.6% of this theme group
Researchers highlight rising drug resistance and challenges in diagnosing and treating infectious diseases.
Disease (84) · Human health (29) · Antibiotic resistance (37) · Medical device (35)
Leishmaniasis: A multifaceted approach to diagnosis, maladies, drug repurposing and way forward
Multitargeting: An Alternative Approach to Tackle Multidrug Resistancein Tuberculosis
| Year | Share index |
|---|---|
| 2022 | 1311.9 |
| 2023 | 1170.0 |
| 2024 | 1054.1 |
| 2025 | 1320.5 |
Common problems researchers identify · 0221.7% of this theme group
Papers point to gaps in technology adoption, access, and policy for digital and mental health services.
Digital health (175) · Health care (224) · Public health (93) · Health administration (49)
The intersection of technology and mental health: enhancing access and care
Digital Healthcare and Patient Transformation: Review Research and Future Agenda
| Year | Share index |
|---|---|
| 2022 | 449.4 |
| 2023 | 435.7 |
| 2024 | 441.9 |
| 2025 | 764.8 |
Common problems researchers identify · 0313.1% of this theme group
Studies note obstacles in applying genomic data to personalized cancer and ocular therapies.
Precision medicine (227) · Personalized medicine (137) · Cancer (39) · Genomics (22)
Advancing precision medicines for ocular disorders: Diagnostic genomics to tailored therapies
Precision medicine in cancer treatment: Revolutionizing care through proteomics, genomics, and personalized therapies
| Year | Share index |
|---|---|
| 2022 | 764.3 |
| 2023 | 1049.9 |
| 2024 | 798.6 |
| 2025 | 777.4 |
Common problems researchers identify · 0411.7% of this theme group
Authors discuss technical and ethical barriers to deploying AI and large‑scale data analytics in clinical care.
Health care (131) · Wearable computer (36) · Big data (33) · Applications of artificial intelligence (24)
Artificial Intelligence in Healthcare: Transforming the Future of Medicine
Artificial intelligence and machine learning in healthcare: a comprehensive review
| Year | Share index |
|---|---|
| 2022 | 43.0 |
| 2023 | 45.3 |
| 2024 | 47.8 |
| 2025 | 86.2 |
Common problems researchers identify · 0510.9% of this theme group
Research flags challenges in translating natural‑product leads and docking methods into viable medicines.
Drug discovery (213) · Drug (105) · Natural product (37) · Drug development (57)
Molecular Docking: Challenges, Advances and its Use in Drug Discovery Perspective
Drug Discovery and Development Processes
| Year | Share index |
|---|---|
| 2022 | 154.6 |
| 2023 | 159.2 |
| 2024 | 166.2 |
| 2025 | 206.1 |
Common problems researchers identify · 0610.0% of this theme group
Works identify infrastructure, regulatory, and acceptance issues hindering remote care expansion.
Telemedicine (193) · Health care (120) · Telehealth (46) · Medical emergency (22)
Telemedicine for healthcare: Capabilities, features, barriers, and applications
Exploring the potential of telemedicine for improved primary healthcare in India: a comprehensive review
| Year | Share index |
|---|---|
| 2022 | 215.3 |
| 2023 | 197.2 |
| 2024 | 209.5 |
| 2025 | 199.0 |
Common problems researchers identify · 078.9% of this theme group
Papers examine the strain COVID‑19 placed on telemedicine systems and the need for resilient frameworks.
Pandemic (159) · Coronavirus disease 2019 (124) · Telemedicine (110) · 2019-20 coronavirus outbreak (21)
Telehealth and the COVID-19 Pandemic: International Perspectives and a Health Systems Framework for Telehealth Implementation to Support Cri
Comprehending Telemedicine: An Online Survey amidst COVID-19 Pandemic
| Year | Share index |
|---|---|
| 2022 | 548.5 |
| 2023 | 379.1 |
| 2024 | 244.3 |
| 2025 | 190.4 |
Cautions · 0122.9% of this theme group
Authors caution about limited validation and potential risks of targeted therapies in oncology.
Pharmacogenomics (12) · Drug (21) · Precision medicine (16) · Cancer (10)
Targeted drug monitoring in oncology for personalized treatment with use of next generation analytics
INVESTIGATIONAL THERAPIES AND TARGETED APPROACHES IN METAPLASTIC BREAST CANCER: A SYSTEMATIC REVIEW OF EMERGING PHARMACOLOGICAL STRATEGIES
| Year | Share index |
|---|---|
| 2022 | 141.0 |
| 2023 | 147.0 |
| 2024 | 157.4 |
| 2025 | 213.9 |
Cautions · 0220.0% of this theme group
Studies warn of algorithmic bias and insufficient transparency when applying AI to clinical decision‑making.
Applications of artificial intelligence (20) · Big data (15) · Precision medicine (26) · Health care (42)
Advancements in the treatment of autoimmune diseases: Integrating artificial intelligence for personalized medicine
Artificial intelligence (AI): using ai to assist in patient assessment, diagnostics, and clinical decision-making
| Year | Share index |
|---|---|
| 2022 | 27.5 |
| 2023 | 30.3 |
| 2024 | 35.4 |
| 2025 | 89.2 |
Cautions · 0314.5% of this theme group
Research questions the effectiveness of remote care for geriatric and postoperative patients.
Telemedicine (54) · Health care (38) · Telerehabilitation (8) · Medical emergency (8)
Telemedicine in Geriatric Psychiatry: Relevance in India
Telemedicine Versus In-Person Visits in Postoperative Care in Orthopedic Patients: Follow-Up Study From North India
| Year | Share index |
|---|---|
| 2022 | 213.6 |
| 2023 | 195.8 |
| 2024 | 207.4 |
| 2025 | 194.7 |
Cautions · 0412.7% of this theme group
Analyses highlight mixed evidence on how digital tools affect patient outcomes and care quality.
Health care (33) · Digital health (18) · Public health (10) · Health informatics (10)
Utilizing Digital Health Technologies To Improve Patient Experience And Care Quality In Global Healthcare: A Systematic Review
An impact of digital technologies on healthcare and patient outcomes: A review
| Year | Share index |
|---|---|
| 2022 | 453.1 |
| 2023 | 438.9 |
| 2024 | 445.9 |
| 2025 | 773.9 |
Cautions · 0510.5% of this theme group
Papers note over‑reliance on AI may overlook critical experimental validation steps.
Drug discovery (35) · Drug (22) · Drug development (11) · Repurposing (8)
Exploring AI-driven approaches to drug discovery and development
The AI-Driven Future of Drug Discovery: Innovations, Applications, and Challenges
| Year | Share index |
|---|---|
| 2022 | 158.5 |
| 2023 | 163.5 |
| 2024 | 171.8 |
| 2025 | 214.7 |
Cautions · 069.9% of this theme group
Authors critique the limited clinical proof and potential dependency associated with digital mental‑health interventions.
Mental health (22) · Psychological intervention (20) · Digital health (20) · Intervention (5)
Digital wellness or digital dependency? a critical examination of mental health apps and their implications
The Role of Technology in Mental Health: Evaluating Digital Interventions for Psychological Well-being
| Year | Share index |
|---|---|
| 2022 | 784.7 |
| 2023 | 800.0 |
| 2024 | 802.5 |
| 2025 | 1143.3 |
Cautions · 079.5% of this theme group
Studies reveal inconsistent patient experiences and acceptance of telemedicine during and after COVID‑19.
Pandemic (32) · Coronavirus disease 2019 (22) · Telemedicine (25) · Telehealth (13)
A Review of Patient Satisfaction and Experience with Telemedicine: A Virtual Solution During and Beyond COVID-19 Pandemic
International survey of audiologists during the COVID-19 pandemic: use of and attitudes to telehealth
| Year | Share index |
|---|---|
| 2022 | 548.5 |
| 2023 | 379.1 |
| 2024 | 244.3 |
| 2025 | 190.4 |
Opportunities · 0117.9% of this theme group
Research explores plant‑derived compounds and peptides as promising sources for new therapeutics.
Drug discovery (338) · Drug (231) · Combinatorial chemistry (69) · Health benefits (48)
Fungal Endophytes as Efficient Sources of Plant-Derived Bioactive Compounds and Their Prospective Applications in Natural Product Drug Disco
Antimicrobial Peptides: The Production of Novel Peptide-Based Therapeutics in Plant Systems
| Year | Share index |
|---|---|
| 2022 | 164.8 |
| 2023 | 169.5 |
| 2024 | 181.6 |
| 2025 | 220.1 |
Opportunities · 0217.6% of this theme group
Papers showcase deep‑learning models and chatbots that could enhance disease detection and personalized care.
Health care (352) · Convolutional neural network (91) · Applications of artificial intelligence (54) · Chatbot (50)
AI in Healthcare: Opportunities and Challenges for Personalized Medicine and Disease Diagnosis
AI-Driven Healthcare Solutions: Utilizing Deep Learning for Predictive Analytics and Personalized Medicine
| Year | Share index |
|---|---|
| 2022 | 36.8 |
| 2023 | 39.0 |
| 2024 | 29.7 |
| 2025 | 47.6 |
Opportunities · 0315.7% of this theme group
Works propose novel biomarkers and computational methods to refine targeted cancer treatments.
Precision medicine (419) · Personalized medicine (304) · Cancer (216) · Biomarker (72)
Addressing Challenges and Opportunities in Precision Medicine Using Deep Learning and Personalized Cancer Treatment
Precision and personalized medicine: new way for cancer management
| Year | Share index |
|---|---|
| 2022 | 764.3 |
| 2023 | 1049.9 |
| 2024 | 798.6 |
| 2025 | 777.4 |
Opportunities · 0413.8% of this theme group
Studies highlight remote care’s potential to improve access, management, and outcomes for long‑term conditions.
Telemedicine (357) · Health care (305) · Telehealth (103) · Digital health (135)
Optimizing healthcare outcomes and broadening nursing capabilities in digital era: telemedicine transformative impact
Advancing Public Health: A Comprehensive Analysis of Telemedicine in Chronic Disease Management, Access Improvement, and Health Promotion Pr
| Year | Share index |
|---|---|
| 2022 | 65.1 |
| 2023 | 64.6 |
| 2024 | 63.7 |
| 2025 | 106.3 |
Opportunities · 0512.9% of this theme group
Research demonstrates virtual docking and simulation as cost‑effective routes to identify antiviral and other drug candidates.
Virtual screening (376) · Docking (374) · In silico (288) · Computational biology (210)
<i>In Silico</i>molecular docking and dynamic analysis of natural compounds against major non-structural proteins of SARS-COV-2
Insights into novel inhibitors intending HCMV protease a computational molecular modelling investigation for antiviral drug repurposing
| Year | Share index |
|---|---|
| 2022 | 28.9 |
| 2023 | 30.4 |
| 2024 | 28.8 |
| 2025 | 32.8 |
Opportunities · 0611.5% of this theme group
Papers emphasize reusing existing drugs and AI‑assisted chemistry to accelerate therapeutic development.
Drug discovery (513) · Drug (300) · Drug development (107) · Drug repositioning (82)
Drug repurposing: An emerging approach to drug discovery
LEVERAGING ARTIFICIAL INTELLIGENCE IN MEDICINAL CHEMISTRY: ADVANCES IN DRUG SYNTHESIS, DEVELOPMENT AND DESIGN
| Year | Share index |
|---|---|
| 2022 | 158.5 |
| 2023 | 163.5 |
| 2024 | 171.8 |
| 2025 | 214.7 |
Opportunities · 0710.6% of this theme group
Works describe wearable and sensor networks that enable continuous health tracking in underserved settings.
Remote patient monitoring (196) · Internet of Things (170) · Wearable computer (170) · Health care (244)
IoT-Driven Smart Healthcare Systems for Remote Patient Monitoring and Management
IoT Based Effective Wearable Healthcare Monitoring System For Remote Areas
| Year | Share index |
|---|---|
| 2022 | 40.1 |
| 2023 | 42.4 |
| 2024 | 45.7 |
| 2025 | 72.4 |
Orientation shares compared with 25,000 papers in the reference sample.
| Research orientation | This field | Reference sample |
|---|---|---|
| Promising | 32.3% | 37.1% |
| Breakthrough | 27.0% | 26.6% |
| Problem-identifying | 21.8% | 9.7% |
| Descriptive | 10.8% | 17.2% |
| Cautionary | 5.2% | 4.5% |
| Comparative | 2.4% | 3.9% |
| Critical | 0.6% | 1.0% |
Counts and shares refer to the stated research pool. A low count describes how much of that research is recorded here, not the absence of a real-world concern.
| Concern / example paper | Papers | Share | Raised as a problem | Worldwide share |
|---|---|---|---|---|
| Privacy & surveillanceSocial Connectedness, Excessive Screen Time During COVID-19 and Mental Health: A Review of Current Evidence | 370 | 3.08% | 131 (35.4%) | 2.66% |
| Safety & misusePolitical dimensions of misinformation, trust, and vaccine confidence in a digital age | 11 | 0.09% | 7 (63.6%) | 0.17% |
| Hardware, e-waste & supply chainE-wastes Management in AI Context: The Opportunities and Challenges in Educational and Healthcare Waste – <i>A Scientifi | 5 | 0.04% | 1 (20.0%) | 0.01% |
| Energy & datacenter footprintSUSTAINABLE GREEN COMPUTING FOR MEDICAL APPLICATIONS: ADVANCING RESPONSIBLE HEALTHCARE IT | 4 | 0.03% | 3 (75.0%) | 0.01% |
| Carbon & emissions of computeFrom Opaqueness to Transparency: Sustainable AI in Diabetes Prediction | 1 | 0.01% | 0 (0.0%) | 0.0% |
| Labour & data workGIG worker protections: designing a new labour category for the digital economy | 1 | 0.01% | 1 (100.0%) | 0.01% |
| Bias & fairnessA Comprehensive Review of Bias and Fairness in Artificial Intelligence for Oral Cancer Detection | 1 | 0.01% | 1 (100.0%) | 0.06% |
| Concentration of compute powerRole of Artificial Intelligence, Big Tech and Machine Learning in Accelerating Biologics Development and Clinical Trials | 1 | 0.01% | 0 (0.0%) | 0.01% |
| Water use | 0 | 0.0% | 0 (%) | 0.0% |
Research orientation and citation rankings describe the covered collection. Its recorded publication dates do not support an overall publication-volume trend.
Institution and researcher rankings use citations to their covered work. Research scope: India. This may be broader than the company geography.
Published patent filings in the recorded source window.
Clear definitions for making better comparisons.
It measures the tracked company ecosystem, recorded funding, hiring and other available evidence. It is not a market-size estimate.
No. A company can belong to several segments, so segment counts and funding can overlap.
A dash or unavailable panel means the current reviewed source snapshot does not support that figure.
Company ecosystem snapshot: 4 August 2026. Funding is recorded in USD; filed accounts retain their stated currency and reporting basis. Each section identifies its own coverage. The news and research behind these sections is explorable in Prism.
Canonical landscape ↗